Works about HER2 positive breast cancer

Results: 970

Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer.

Published in:

Breast Cancer Research, 2025, v. 27, n. 1, p. 1, doi. 10.1186/s13058-025-02025-6

By:

Jeong, Jaekwang;
Yoo, Kwangmin;
Lee, Jongwon;
Shin, Jae Hun;
Choi, Jungmin;
Wysolmerski, John

Publication type:

Article

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience.

Published in:

BMC Health Services Research, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12913-025-12876-6

By:

Yaghoubi, Neda;
Fatemi, Behzad;
Ahmadi, Razieh;
Metghalchi, Yalda;
Shahrami, Bita;
Vaezi, Mohammad;
Rezaei, Soheila

Publication type:

Article

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study.

Published in:

Cancer Research & Treatment, 2025, v. 57, n. 2, p. 434, doi. 10.4143/crt.2024.340

By:

Hao, Chunfang;
Wang, Xu;
Shi, Yehui;
Tong, Zhongsheng;
Li, Shufen;
Liu, Xiaodong;
Zhang, Lan;
Zhang, Jie;
Meng, Wenjing;
Zhang, Li

Publication type:

Article

Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review.

Published in:

2025

By:

Luo, Simin;
Chai, Jie;
Ding, Linxiaoxiao;
Tang, Song

Publication type:

Case Study

Systematic Review of the Antitumor Activities and Mechanisms of Scorpion Venom on Human Breast Cancer Cells Lines (In Vitro Study).

Published in:

Journal of Clinical Medicine, 2025, v. 14, n. 9, p. 3181, doi. 10.3390/jcm14093181

By:

Kwon, Na-Yoen;
Sung, Hyun-Kyung;
Park, Jang-Kyung

Publication type:

Article

Study on heterogeneity of vascularity and cellularity via multiparametric MRI habitat imaging in breast cancer.

Published in:

BMC Medical Imaging, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12880-025-01698-x

By:

Zhang, Xiaolei;
Chen, Xiaoyan;
Fu, Yao;
Zhou, Han;
Lin, Yan

Publication type:

Article

Genetic insights into BRCA1/2 associated breast cancer in Türkiye: focus on early-onset and aggressive subtypes.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02192-0

By:

Celik Demirbas, Betul;
Kilic Erciyas, Seda;
Sukruoglu Erdogan, Ozge;
Pasin, Ozge;
Yalniz Kayim, Zubeyde;
Özgel, Merve Çiğdem;
Tuncer, Seref Bugra

Publication type:

Article

Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment.

Published in:

NPJ Breast Cancer, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41523-025-00760-9

By:

Taurelli Salimbeni, Beatrice;
Giudici, Fabiola;
Pescia, Carlo;
Berton Giachetti, Pier Paolo Maria;
Scafetta, Roberta;
Zagami, Paola;
Marra, Antonio;
Trapani, Dario;
Esposito, Angela;
Scagnoli, Simone;
Cerbelli, Bruna;
Botticelli, Andrea;
Munzone, Elisabetta;
Fusco, Nicola;
Criscitiello, Carmen;
Curigliano, Giuseppe

Publication type:

Article

Editorial: NK cells in the tumor microenvironment: immunosuppressive mechanisms and therapeutic opportunities.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1606236

By:

Ayuso, Jose M.;
De Waele, Jorrit

Publication type:

Article

Immunohistochemical expression of epidermal growth factor receptor: prognostic value in HER2 positive breast cancer.

Published in:

Journal of Immunoassay & Immunochemistry, 2025, v. 46, n. 3, p. 262, doi. 10.1080/15321819.2025.2475291

By:

Houcine, Yoldez;
Ben Salem, Hend;
El Fekih, Sirine;
Maaoui, Amal;
Driss, Maha

Publication type:

Article

Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry.

Published in:

Breast Cancer: Targets & Therapy, 2025, v. 17, p. 253, doi. 10.2147/BCTT.S507189

By:

Tsai, Yi-Fang;
Hsu, Chih-Yi;
Chiu, Yun-Ning;
Huang, Chi-Cheng;
Chou, Shih-Hsiang;
Lin, Yen-Shu;
Chao, Ta-Chung;
Liu, Chun-Yu;
Chiu, Jen-Hwey;
Tseng, Ling-Ming

Publication type:

Article

Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer.

Published in:

Breast Cancer: Targets & Therapy, 2025, v. 17, p. 201, doi. 10.2147/BCTT.S503150

By:

Gu, Huayan;
Zhu, Teng;
Ding, JiaLing;
Yang, Zhi;
Qi, Shuangyi;
Guo, Guilong

Publication type:

Article

In silico de novo drug design of a therapeutic peptide inhibitor against UBE2C in breast cancer.

Published in:

Journal of Bioinformatics & Computational Biology, 2023, v. 21, n. 1, p. 1, doi. 10.1142/S0219720022500299

By:

Añonuevo, Andrea Mae;
Gomez, Marineil;
Tayo, Lemmuel L.

Publication type:

Article

Evaluation and Simulation of Docking Peptide Labeled with Technetium-99m (Tc-99m) with Human Epidermal Growth Factor Receptor 2 (HER2) in HER2-Positive Breast Cancer Cells.

Published in:

Jentashapir Journal of Cellular & Molecular Biology, 2023, v. 14, n. 4, p. 1, doi. 10.5812/jjcmb-139817

By:

Reyhani, Mohammad Mehdi;
Minaeefar, Amir Abbas;
Dadfar, Fereshteh;
Bamdad, Kourosh

Publication type:

Article

Recent Advances and Future Perspectives in Radiolabeled Antibody Fragments for Breast Cancer Molecular Imaging.

Published in:

Frontiers in Biomedical Technologies, 2024, v. 11, n. 4, p. 677, doi. 10.18502/fbt.v11i4.16517

By:

Gerami, Reza;
Altafi, Mana;
Shahpar, Zahra;
Izadpanah, Ensieh;
Soltani, Siamak;
Naderloo, Omid;
Tarighatnia, Ali

Publication type:

Article

Correction.

Published in:: Immunopharmacology & Immunotoxicology, 2023, v. 45, n. 5, p. I, doi. 10.1080/08923973.2022.2126619
Publication type:: Article

Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab.

Published in:

Immunopharmacology & Immunotoxicology, 2023, v. 45, n. 5, p. 616, doi. 10.1080/08923973.2023.2183352

By:

Jiang, Shuai;
Geng, Shuai;
Gao, Xinyue;
Liu, Tong;
Luo, Xinyu;
Wang, Nan;
Shi, Ning;
Dong, Mei

Publication type:

Article

Correction.

Published in:: 2022
Publication type:: Correction Notice

Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.

Published in:

Immunopharmacology & Immunotoxicology, 2022, v. 44, n. 6, p. 809, doi. 10.1080/08923973.2022.2090956

By:

Liu, Tong;
Liu, Duo;
Jin, Yao;
Dong, Mei

Publication type:

Article

Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice.

Published in:

Immunopharmacology & Immunotoxicology, 2020, v. 42, n. 4, p. 346, doi. 10.1080/08923973.2020.1775644

By:

Özverel, Cenk Serhan;
Uyanikgil, Yiğit;
Karaboz, İsmail;
Nalbantsoy, Ayse

Publication type:

Article

CYB561 promotes HER2+ breast cancer proliferation by inhibiting H2AFY degradation.

Published in:

Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01804-y

By:

Zhao, Ting;
Wang, Chaomin;
Zhao, Na;
Qiao, Ge;
Hua, Jialei;
Meng, Donghua;
Liu, Liming;
Zhong, Benfu;
Liu, Miao;
Wang, Yichao;
Bai, Changsen;
Li, Yueguo

Publication type:

Article

Therapeutic management challenges in a polyallergic HER2-positive breast cancer patient.

Published in:

Oncolog-Hematolog, 2024, n. 69, p. 46

By:

Stejeroiu, Mihaela-Andreea

Publication type:

Article

Surprising results in the management of HER2-positive, hormone receptor-positive breast cancer progressing to metastatic disease.

Published in:

Oncolog-Hematolog, 2024, n. 69, p. 31

By:

Geală, Andreea-Ioana;
Matei, R.;
Stolojanu, Anca;
Siminiceanu, Crina;
Ciontea, Loredana;
Dumitrescu, Elena;
Prundianu, Sânziana;
Stănculeanu, Dana-Lucia

Publication type:

Article

Trastuzumab deruxtecan (T-DXd) – a single-center real-world data experience in HER2-positive patients.

Published in:

Oncolog-Hematolog, 2024, n. 69, p. 35

By:

Lupu, Vlad;
Oprean, Cristina

Publication type:

Article

Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients.

Published in:

Molecular & Cellular Oncology, 2024, v. 11, n. 1, p. 1, doi. 10.1080/23723556.2024.2309715

By:

Song, Yu;
Geng, Qiao-Chen;
An, Wen-Jing;
Zhang, Fu-Cheng;
Jiang, Ran;
Zhao, Rui-Sheng;
Deng, Zhi-Jian;
Li, Heng

Publication type:

Article

DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer.

Published in:

Cancer Biology & Medicine, 2025, v. 22, n. 3, p. 231, doi. 10.20892/j.issn.2095-3941.2024.0586

By:

Xi Li;
Liwen Liang;
Zhongyuan Zhu;
Haiqing Hua;
Yang Qiu

Publication type:

Article

Antibody-drug conjugates in breast cancer: advances and prospects.

Published in:

Cancer Biology & Medicine, 2025, v. 22, n. 2, p. 83, doi. 10.20892/j.issn.2095-3941.2024.0486

By:

Zhiqiang Shi;
Yongjin Lu;
Qiuchen Zhao;
Yongsheng Wang;
Pengfei Qiu

Publication type:

Article

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China.

Published in:

Cancer Biology & Medicine, 2024, v. 21, n. 10, p. 838, doi. 10.20892/j.issn.2095-3941.2024.0374

By:

Jianbin Li;
Zefei Jiang

Publication type:

Article

Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment.

Published in:

Cancer Biology & Medicine, 2024, v. 21, n. 10, p. 831, doi. 10.20892/j.issn.2095-3941.2024.0327

By:

Zhihong Luo;
Ke Gong

Publication type:

Article

Evolving molecular subtyping of breast cancer advances precision treatment.

Published in:

Cancer Biology & Medicine, 2024, v. 21, n. 9, p. 731, doi. 10.20892/j.issn.2095-3941.2024.0222

By:

Rui Shan;
Lei-Jie Dai;
Zhi-Ming Shao;
Yi-Zhou Jiang

Publication type:

Article

Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer.

Published in:

Cancer Biology & Medicine, 2023, v. 20, n. 10, p. 689, doi. 10.20892/j.issn.2095-3941.2023.0286

By:

Lei-Jie Dai;
Yu-Wei Li;
Ding Ma;
Zhi-Ming Shao;
Yi-Zhou Jiang

Publication type:

Article

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification.

Published in:

Cancer Biology & Medicine, 2022, v. 19, n. 6, p. 769, doi. 10.20892/j.issn.2095-3941.2022.0277

By:

Jianbin Li;
Zefei Jiang

Publication type:

Article

Annular atrophic lichen planus induced by anti‐HER2 antibodies.

Published in:

Australasian Journal of Dermatology, 2021, v. 62, n. 2, p. 210, doi. 10.1111/ajd.13501

By:

Chawla, Sumir;
Turner, Nicholas;
Terlizzo, Monica;
Heelan, Kara

Publication type:

Article

Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-57343-0

By:

Pang, Jian;
Ding, Nianhua;
Yin, Nana;
Xiao, Zhi

Publication type:

Article

A comprehensive analysis of the role of QPRT in breast cancer.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-42566-4

By:

Yan, Yiqing;
Li, Lun;
Wang, Zixin;
Pang, Jian;
Guan, Xinyu;
Yuan, Yunchang;
Xia, Zhenkun;
Yi, Wenjun

Publication type:

Article

Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-46460-x

By:

Rojhannezhad, Mahdieh;
Soltani, Bahram M.;
Vasei, Mohammad;
Ghorbanmehr, Nassim;
Mowla, Seyed Javad

Publication type:

Article

A comprehensive analysis of the role of QPRT in breast cancer.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-42566-4

By:

Yan, Yiqing;
Li, Lun;
Wang, Zixin;
Pang, Jian;
Guan, Xinyu;
Yuan, Yunchang;
Xia, Zhenkun;
Yi, Wenjun

Publication type:

Article

Lateral interactions between CD276 and CD147 are essential for stemness in breast cancer: a novel insight from proximal proteome analysis.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-41416-7

By:

Seo, Yu Ri;
Lee, Junghyeon;
Ryu, Han Suk;
Kim, EunHee G.;
Kim, So Hyun;
Jeong, Jieun;
Jung, Hyeryeon;
Jung, YeoJin;
Kim, Han Byeol;
Jo, Yeon Hui;
Kim, Yeong Dong;
Jin, Min-Sun;
Lee, Yong Yook;
Kim, Kristine M.;
Yi, Eugene C.

Publication type:

Article

Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40071-2

By:

Orrù, Sandra;
Pascariello, Emanuele;
Pes, Barbara;
Rallo, Vincenzo;
Barbara, Raffaele;
Muntoni, Marta;
Notari, Francesca;
Fancello, Gianfranco;
Mocci, Cristina;
Muroni, Maria Rosaria;
Cossu-Rocca, Paolo;
Angius, Andrea;
De Miglio, Maria Rosaria

Publication type:

Article

Predictive biological factors for late survival in patients with HER2-positive breast cancer.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-38200-y

By:

Kang, Young-Joon;
Oh, Se Jeong;
Bae, Soo Youn;
Kim, Eun-Kyu;
Lee, Young-Jin;
Park, Eun Hwa;
Jeong, Joon;
Park, Heung Kyu;
Suh, Young Jin;
Kim, Yong-Seok

Publication type:

Article

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-35715-2

By:

Dogan, Izzet;
Aydin, Esra;
Khanmammadov, Nijat;
Paksoy, Nail;
Saip, Pinar;
Aydiner, Adnan

Publication type:

Article

The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.

Published in:

Histopathology, 2025, v. 86, n. 7, p. 1112, doi. 10.1111/his.15417

By:

Ai, Di;
Arrey, Eliel N;
Postlewait, Lauren M;
Gao, Yuan;
Li, Xiaoxian

Publication type:

Article

Serous‐like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours.

Published in:

Histopathology, 2025, v. 86, n. 5, p. 779, doi. 10.1111/his.15385

By:

Krings, Gregor;
Shamir, Eliah R.;
Laé, Marick;
Bean, Gregory R.;
Post, Miriam D.;
Schnitt, Stuart J.;
Chen, Yunn‐Yi

Publication type:

Article

Editorial: New strategies for reversing cancer therapy resistance.

Published in:

Frontiers in Pharmacology, 2024, p. 01, doi. 10.3389/fphar.2024.1411519

By:

Yue Du;
Xiujun Liu;
Lulu Wang;
Shengxi Chen

Publication type:

Article

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2023.1332539

By:

Yan Liang;
Purong Zhang;
Feng Li;
Houyun Lai;
Tingting Qi;
Yixin Wang

Publication type:

Article

Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis.

Published in:

Frontiers in Pharmacology, 2023, p. 01, doi. 10.3389/fphar.2023.1090326

By:

Sudewi Mukaromah Khoirunnisa;
Fithria Dyah Ayu Suryanegara;
Didik Setiawan;
Maarten Jacobus Postma

Publication type:

Article

The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis.

Published in:

EJNMMI Research, 2023, v. 13, n. 1, p. 1, doi. 10.1186/s13550-023-00953-y

By:

de Mooij, Cornelis M.;
Ploumen, Roxanne A. W.;
Nelemans, Patty J.;
Mottaghy, Felix M.;
Smidt, Marjolein L.;
van Nijnatten, Thiemo J. A.

Publication type:

Article

Value of <sup>18</sup>F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype.

Published in:

EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00861-z

By:

de Mooij, Cornelis M.;
Mitea, Cristina;
Mottaghy, Felix M.;
Smidt, Marjolein L.;
van Nijnatten, Thiemo J. A.

Publication type:

Article

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer.

Published in:

Lung Cancer: Targets & Therapy, 2021, v. 12, p. 103, doi. 10.2147/LCTT.S307324

By:

Azar, Ibrahim;
Alkassis, Samer;
Fukui, Jami;
Alsawah, Fares;
Fedak, Kalub;
Hallak, Mohammed Najeeb Al;
Sukari, Ammar;
Nagasaka, Misako

Publication type:

Article

Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.

Published in:

Cancer Research & Treatment, 2024, v. 56, n. 3, p. 795, doi. 10.4143/crt.2023.1151

By:

Ruyan Zhang;
Xiaoran Liu;
Guohong Song;
Yan Zhang;
Huiping Li

Publication type:

Article